Abbonarsi

Network study of nasal transcriptome profiles reveals master regulator genes of asthma - 04/03/21

Doi : 10.1016/j.jaci.2020.07.006 
Anh N. Do, PhD a, b, Yoojin Chun, MS a, b, Galina Grishina, MS c, Alexander Grishin, PhD c, Angela J. Rogers, MD, MPH d, Benjamin A. Raby, MD, MPH e, Scott T. Weiss, MD, MS f, g, Alfin Vicencio, MD h, Eric E. Schadt, PhD a, b, Supinda Bunyavanich, MD, MPH, MPhil a, b, c,
a Icahn Institute for Genomics and Multiscale Biology, Icahn School of Medicine at Mount Sinai, New York, NY 
b Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, NY 
c Division of Allergy and Immunology, Department of Pediatrics, Icahn School of Medicine at Mount Sinai, New York, NY 
d Division of Pulmonary and Critical Care Medicine, Department of Medicine, Stanford University School of Medicine, Stanford, Calif 
e Division of Pulmonary Medicine, Children’s Hospital Boston, Boston, Mass 
f Channing Division of Network Medicine, Brigham and Women’s Hospital, and Harvard Medical School, Boston, Mass 
g Division of Pulmonary and Critical Care Medicine, Brigham and Women’s Hospital, and Harvard Medical School, Boston, Mass 
h Division of Pulmonary Medicine, Department of Pediatrics, Icahn School of Medicine at Mount Sinai, New York, NY 

Corresponding author: Supinda Bunyavanich, MD, MPH, MPhil, Icahn School of Medicine at Mount Sinai, 1425 Madison Ave, Box 1498, New York, NY 10029.Icahn School of Medicine at Mount Sinai1425 Madison AveBox 1498New YorkNY10029

Abstract

Background

Nasal transcriptomics can provide an accessible window into asthma pathobiology.

Objective

Our goal was to move beyond gene signatures of asthma to identify master regulator genes that causally regulate genes associated with asthma phenotypes.

Methods

We recruited 156 children with severe persistent asthma and controls for nasal transcriptome profiling and applied network-based and probabilistic causal methods to identify severe asthma genes and their master regulators. We then took the same approach in an independent cohort of 190 adults with mild/moderate asthma and controls to identify mild/moderate asthma genes and their master regulators. Comparative analysis of the master regulator genes followed by validation testing in independent children with severe asthma (n = 21) and mild/moderate asthma (n = 154) was then performed.

Results

Nasal gene signatures for severe persistent asthma and for mild/moderate persistent asthma were identified; both were found to be enriched in coexpression network modules for ciliary function and inflammatory response. By applying probabilistic causal methods to these gene signatures and validation testing in independent cohorts, we identified (1) a master regulator gene common to asthma across severity and ages (FOXJ1); (2) master regulator genes of severe persistent asthma in children (LRRC23, TMEM231, CAPS, PTPRC, and FYB); and (3) master regulator genes of mild/moderate persistent asthma in children and adults (C1orf38 and FMNL1). The identified master regulators were statistically inferred to causally regulate the expression of downstream genes that modulate ciliary function and inflammatory response to influence asthma.

Conclusion

The identified master regulator genes of asthma provide a novel path forward to further uncovering asthma mechanisms and therapy.

Il testo completo di questo articolo è disponibile in PDF.

Graphical abstract




Il testo completo di questo articolo è disponibile in PDF.

Key words : Asthma, nasal, transcriptome, network, gene expression, severe persistent asthma, mild persistent asthma, moderate persistent asthma, master regulator, probabilistic causal network

Abbreviations used : ARIA, ATOM, FDR, GO, KDA, |log2 FC|, RNA-seq, WGCNA


Mappa


 This work was funded by the US National Institutes of Health NIH R01 AI 118833.
 Disclosure of potential conflict of interest: The authors declare that they have no relevant conflicts of interest.


© 2020  American Academy of Allergy, Asthma & Immunology. Pubblicato da Elsevier Masson SAS. Tutti i diritti riservati.
Aggiungere alla mia biblioteca Togliere dalla mia biblioteca Stampare
Esportazione

    Citazioni Export

  • File

  • Contenuto

Vol 147 - N° 3

P. 879-893 - Marzo 2021 Ritorno al numero
Articolo precedente Articolo precedente
  • mRNA COVID-19 vaccine is well tolerated in patients with cutaneous and systemic mastocytosis with mast cell activation symptoms and anaphylaxis
  • Tiago Azenha Rama, André Moreira, Mariana Castells
| Articolo seguente Articolo seguente
  • Genetic analyses identify GSDMB associated with asthma severity, exacerbations, and antiviral pathways
  • Xingnan Li, Stephanie A. Christenson, Brian Modena, Huashi Li, William W. Busse, Mario Castro, Loren C. Denlinger, Serpil C. Erzurum, John V. Fahy, Benjamin Gaston, Annette T. Hastie, Elliot Israel, Nizar N. Jarjour, Bruce D. Levy, Wendy C. Moore, Prescott G. Woodruff, Naftali Kaminski, Sally E. Wenzel, Eugene R. Bleecker, Deborah A. Meyers, NHLBI Severe Asthma Research Program (SARP)

Benvenuto su EM|consulte, il riferimento dei professionisti della salute.
L'accesso al testo integrale di questo articolo richiede un abbonamento.

Già abbonato a @@106933@@ rivista ?

Il mio account


Dichiarazione CNIL

EM-CONSULTE.COM è registrato presso la CNIL, dichiarazione n. 1286925.

Ai sensi della legge n. 78-17 del 6 gennaio 1978 sull'informatica, sui file e sulle libertà, Lei puo' esercitare i diritti di opposizione (art.26 della legge), di accesso (art.34 a 38 Legge), e di rettifica (art.36 della legge) per i dati che La riguardano. Lei puo' cosi chiedere che siano rettificati, compeltati, chiariti, aggiornati o cancellati i suoi dati personali inesati, incompleti, equivoci, obsoleti o la cui raccolta o di uso o di conservazione sono vietati.
Le informazioni relative ai visitatori del nostro sito, compresa la loro identità, sono confidenziali.
Il responsabile del sito si impegna sull'onore a rispettare le condizioni legali di confidenzialità applicabili in Francia e a non divulgare tali informazioni a terzi.


Tutto il contenuto di questo sito: Copyright © 2024 Elsevier, i suoi licenziatari e contributori. Tutti i diritti sono riservati. Inclusi diritti per estrazione di testo e di dati, addestramento dell’intelligenza artificiale, e tecnologie simili. Per tutto il contenuto ‘open access’ sono applicati i termini della licenza Creative Commons.